IOVA

Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.

Wall Street analysts forecast IOVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOVA is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Iovance Biotherapeutics Inc revenue for the last quarter amounts to 67.46M USD, increased 15.20 % YoY.

Iovance Biotherapeutics Inc. EPS for the last quarter amounts to -0.25 USD, decreased -10.71 % YoY.

Iovance Biotherapeutics Inc (IOVA) has 838 emplpoyees as of December 15 2025.

Today IOVA has the market capitalization of 873.33M USD.